FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:984-987 March 8, 2007 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Audio Interview Perspective by Lagerqvist, B. Perspective by Mauri, L. Perspective by Kastrati, A. Perspective by Spaulding, C. Perspective by Stone, G. W. Editorial by Curfman, G. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lagerqvist, B. Related Article by Mauri, L. Related Article by Kastrati, A. Related Article by Spaulding, C. Related Article by Stone, G. W. PubMed Citation

In the light of recent studies suggesting that drug-eluting stents may pose a risk of thrombosis that was not observed during pre-market testing, the Food and Drug Administration (FDA) convened a meeting of its Circulatory System Devices Advisory Panel on December 7 and 8, 2006, to examine the safety of these devices. The FDA will carefully consider the information and views presented at the meeting in deciding on future actions.

An understanding of the mechanisms of neointimal growth within bare-metal stents led to the development of drug-eluting stents designed to reduce restenosis rates. Both drug-eluting stents approved by the FDA . . . [Full Text of this Article]

Source Information

Dr. Farb is a medical officer, and Ms. Boam the chief of the Interventional Cardiology Devices Branch, of the Office of Device Evaluation, Center for Devices and Radiological Health, FDA, Rockville, MD.

A discussion between Dr. Donald Baim, chief medical and scientific officer of Boston Scientific, and Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, on the risks and benefits of drug-eluting stents can be heard at www.nejm.org.

This article (10.1056/NEJMp068304) was published at www.nejm.org on February 12, 2007.

This article has been cited by other articles:

• Chieffo, A., Park, S.-J., Meliga, E., Sheiban, I., Lee, M. S., Latib, A., Kim, Y.-H., Valgimigli, M., Sillano, D., Magni, V., Biondi-Zoccai, G., Montorfano, M., Airoldi, F., Rogacka, R., Carlino, M., Michev, I., Lee, C.-W., Hong, M.-K., Park, S.-W., Moretti, C., Bonizzoni, E., Sangiorgi, G. M., Tobis, J., Serruys, P. W., Colombo, A. (2008). Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. Eur Heart J 29: 2108-2115 [Abstract] [Full Text]  
• Veitch, A M, Baglin, T P, Gershlick, A H, Harnden, S M, Tighe, R, Cairns, S (2008). Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 57: 1322-1329 [Full Text]  
• Newsome, L. T., Kutcher, M. A., Royster, R. L. (2008). Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention. Anesth. Analg. 107: 552-569 [Abstract] [Full Text]  
• Joner, M., Nakazawa, G., Finn, A. V., Quee, S. C., Coleman, L., Acampado, E., Wilson, P. S., Skorija, K., Cheng, Q., Xu, X., Gold, H. K., Kolodgie, F. D., Virmani, R. (2008). Endothelial Cell Recovery Between Comparator Polymer-Based Drug-Eluting Stents. J Am Coll Cardiol 52: 333-342 [Abstract] [Full Text]  
• Nappi, J. (2008). Benefits and limitations of current antiplatelet therapies. Am J Health Syst Pharm 65: S5-S10 [Abstract] [Full Text]  
• Mahmud, E., Bromberg-Marin, G., Palakodeti, V., Ang, L., Creanga, D., DeMaria, A. N. (2008). Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.. J Am Coll Cardiol 51: 2385-2395 [Abstract] [Full Text]  
• Dixon, S. R., Grines, C. L., O'Neill, W. W. (2008). The year in interventional cardiology.. J Am Coll Cardiol 51: 2355-2369 [Full Text]  
• Li, J., Jabara, R., Pendyala, L., Otsuka, Y., Shinke, T., Hou, D., Robinson, K., Chronos, N. (2008). Abnormal Vasomotor Function of Porcine Coronary Arteries Distal to Sirolimus-Eluting Stents. J Am Coll Cardiol Intv 1: 279-285 [Abstract] [Full Text]  
• Filipe, C., Lam Shang Leen, L., Brouchet, L., Billon, A., Benouaich, V., Fontaine, V., Gourdy, P., Lenfant, F., Arnal, J.-F., Gadeau, A.-P., Laurell, H. (2008). Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium. Am. J. Physiol. Heart Circ. Physiol. 294: H2822-H2830 [Abstract] [Full Text]  
• Groeneveld, P. W., Matta, M. A., Greenhut, A. P., Yang, F. (2008). Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients. J Am Coll Cardiol 51: 2017-2024 [Abstract] [Full Text]  
• Mark, D. B. (2008). Interpreting the Music of Drug-Eluting Stents: Halcyon Song or Albatross Dirge?. J Am Coll Cardiol 51: 1854-1856 [Full Text]  
• Patel, M. R., Holmes, D. R. Jr (2008). Next-Generation Drug-Eluting Stents: A Spirited Step Forward or More of the Same. JAMA 299: 1952-1953 [Full Text]  
• Valgimigli, M., Campo, G., Percoco, G., Bolognese, L., Vassanelli, C., Colangelo, S., de Cesare, N., Rodriguez, A. E., Ferrario, M., Moreno, R., Piva, T., Sheiban, I., Pasquetto, G., Prati, F., Nazzaro, M. S., Parrinello, G., Ferrari, R., for the Multicentre Evaluation of Single High-Dose, (2008). Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction: The MULTISTRATEGY Randomized Trial. JAMA 299: 1788-1799 [Abstract] [Full Text]  
• Taggart, D. P., Kaul, S., Boden, W. E., Ferguson, T. B. Jr, Guyton, R. A., Mack, M. J., Sergeant, P. T., Shemin, R. J., Smith, P. K., Yusuf, S. (2008). Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery.. J Am Coll Cardiol 51: 885-892 [Abstract] [Full Text]  
• Taggart, D. P. (2008). Does prior PCI increase the risk of subsequent CABG?. Eur Heart J 29: 573-575 [Full Text]  
• Applegate, R. J., Sacrinty, M. T., Kutcher, M. A., Santos, R. M., Gandhi, S. K., Baki, T. T., Little, W. C. (2008). "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents.. J Am Coll Cardiol 51: 607-614 [Abstract] [Full Text]  
• Melikian, N, Wijns, W (2008). Drug-eluting stents: a critique. Heart 94: 145-152 [Abstract] [Full Text]  
• Marroquin, O. C., Selzer, F., Mulukutla, S. R., Williams, D. O., Vlachos, H. A., Wilensky, R. L., Tanguay, J.-F., Holper, E. M., Abbott, J. D., Lee, J. S., Smith, C., Anderson, W. D., Kelsey, S. F., Kip, K. E. (2008). A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications. NEJM 358: 342-352 [Abstract] [Full Text]  
• Carrozza, J. P. Jr. (2008). Drug-Eluting Stents -- Pushing the Envelope beyond the Labels?. NEJM 358: 405-407 [Full Text]  
• Gitt, A. K., Betriu, A. (2008). Antiplatelet therapy in acute coronary syndromes. Eur Heart J Suppl 10: A4-A12 [Abstract] [Full Text]  
• Unger, F. (2007). Drug eluting stents a nightmare?. ICVTS 6: 813-814 [Abstract] [Full Text]  
• Egashira, K., Nakano, K., Ohtani, K., Funakoshi, K., Zhao, G., Ihara, Y., Koga, J.-i., Kimura, S., Tominaga, R., Sunagawa, K. (2007). Local Delivery of Anti-Monocyte Chemoattractant Protein-1 by Gene-Eluting Stents Attenuates In-Stent Stenosis in Rabbits and Monkeys. Arterioscler. Thromb. Vasc. Bio. 27: 2563-2568 [Abstract] [Full Text]  
• Buttner, H. J., Neumann, F.-J. (2007). Peeling-Off Labels: Mounting Evidence for Benefit of Drug-Eluting Stents With Off-Label Use. J Am Coll Cardiol 50: 2037-2038 [Full Text]  
• Tu, J. V., Bowen, J., Chiu, M., Ko, D. T., Austin, P. C., He, Y., Hopkins, R., Tarride, J.-E., Blackhouse, G., Lazzam, C., Cohen, E. A., Goeree, R. (2007). Effectiveness and Safety of Drug-Eluting Stents in Ontario. NEJM 357: 1393-1402 [Abstract] [Full Text]  
• Farag, N., Delbanco, T., Carrozza, J. P. Jr (2007). Update: A 69-Year-Old Woman With Left Main Coronary Artery Disease. JAMA 298: 1558-1559 [Full Text]  
• Giugliano, R. P., Braunwald, E. (2007). The Year in Non ST-Segment Elevation Acute Coronary Syndrome. J Am Coll Cardiol 50: 1386-1395 [Full Text]  
• Alcalai, R., Planer, D., Pollak, A., Lotan, C. (2007). Nonspecific Troponin Elevation Reply. Arch Intern Med 167: 1907-1907 [Full Text]  
• Daemen, J., Serruys, P. W. (2007). Drug-Eluting Stent Update 2007: Part II: Unsettled Issues. Circulation 116: 961-968 [Full Text]  
• Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E. Jr, Chavey, W. E. II, Fesmire, F. M., Hochman, J. S., Levin, T. N., Lincoff, A. M., Peterson, E. D., Theroux, P., Wenger, N. K., Wright, R. S., Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2007). ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 50: e1-e157 [Full Text]  
• Bode, C., Zehender, M. (2007). The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. Eur Heart J Suppl 9: D10-D19 [Abstract] [Full Text]  
• Spinler, S. A., Wilensky, R. L. (2007). Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent. Am J Health Syst Pharm 64: 1432-1434 [Full Text]  
• (2007). JournalScan. Heart 93: 890-892 [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Krucoff, M. W., Boam, A., Schultz, D. G. (2007). Drug-Eluting Stents "Deliver Heartburn": How Do We Spell Relief Going Forward?. Circulation 115: 2990-2994 [Full Text]  
• Curfman, G. D., Morrissey, S., Jarcho, J. A., Drazen, J. M. (2007). Drug-Eluting Coronary Stents -- Promise and Uncertainty. NEJM 356: 1059-1060 [Full Text]  
• (2007). Latest Findings on Stents. JWatch General 2007: 1-1 [Full Text]